Ophir Keret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ophir Keret has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Amir Glik
Rabin Medical Center
2 shared publications- Amir Glik
The Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel
2 shared publications Israel Steiner
Cognitive Neurology Clinic, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel
2 shared publications- Jonathan Naftali
Department of Neurology, Rabin Medical Center, Petach Tikva, Israel
2 shared publications Tzippy Shochat
Statistical Consultancy Service, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel
2 shared publicationsAlin Perlov
Rabin medical center, Petach Tikva Israel
1 shared publication
Latest Publications
- 9 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (4) , 1872-1880
Real-world clinical profile of individuals with cerebrospinal fluid Aβ – /pTau181 +
Background: Cerebrospinal fluid (CSF) pTau181 is used to support Alzheimer's disease (AD) diagnosis but can also rise in amyloid-negative individuals. This CSF profile (Aβ − /pTau181 + ) lies outside the AD continuum and complicates real-world etiologic diagnosis of neurocognitive disorders. Objective: To determine the prevalence and clinical phenotype associated with the Aβ − /pTau181 + CSF biomarker profile in a real-world memory clinic population. Methods: We screened the Mount Sinai Hospital database (2015–2024) for patients who underwent ADmark CSF biomarker testing. An Aβ − /pTau181 + group was classified using assay cutoffs (Amyloid-Total-Tau Index>1.2, pTau181 > 54 pg/mL) and compared to an Aβ + group (Amyloid-Total-Tau Index− /pTau181 + group included 25 individuals (10.1% of the cohort) and had equally impaired cognition but fewer episodic memory complaints. Diagnosis was more often Lewy body or frontotemporal dementia. On neuroimaging, Aβ − /pTau181 + exhibited less white matter hyperintensity burden and temporoparietal atrophy. Conclusions: CSF Aβ − /pTau181 + is frequent in real-world evaluations of cognitive impairment and presents with fewer AD phenotypic features. Further research is required to clarify Aβ − /pTau181 + underlying biology and clinical trajectory.
- 9 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 111 (4) , 1872-1880
Real-world clinical profile of individuals with cerebrospinal fluid Aβ – /pTau181 +
Background: Cerebrospinal fluid (CSF) pTau181 is used to support Alzheimer's disease (AD) diagnosis but can also rise in amyloid-negative individuals. This CSF profile (Aβ − /pTau181 + ) lies outside the AD continuum and complicates real-world etiologic diagnosis of neurocognitive disorders. Objective: To determine the prevalence and clinical phenotype associated with the Aβ − /pTau181 + CSF biomarker profile in a real-world memory clinic population. Methods: We screened the Mount Sinai Hospital database (2015–2024) for patients who underwent ADmark CSF biomarker testing. An Aβ − /pTau181 + group was classified using assay cutoffs (Amyloid-Total-Tau Index>1.2, pTau181 > 54 pg/mL) and compared to an Aβ + group (Amyloid-Total-Tau Index− /pTau181 + group included 25 individuals (10.1% of the cohort) and had equally impaired cognition but fewer episodic memory complaints. Diagnosis was more often Lewy body or frontotemporal dementia. On neuroimaging, Aβ − /pTau181 + exhibited less white matter hyperintensity burden and temporoparietal atrophy. Conclusions: CSF Aβ − /pTau181 + is frequent in real-world evaluations of cognitive impairment and presents with fewer AD phenotypic features. Further research is required to clarify Aβ − /pTau181 + underlying biology and clinical trajectory.
- Open Access
- 6 November 2025
- Published by Taylor & Francis in Aphasiology
- Vol. 40 (12) , 2366-2392
Classification of lexical retrieval impairments in primary progressive aphasia
- 6 November 2025
- Published by Taylor & Francis in Aphasiology
- Vol. 40 (12) , 2366-2392
Open AccessClassification of lexical retrieval impairments in primary progressive aphasia
- Open Access
- 14 October 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (10) , e70773
Impact of cerebral small vessel disease on cognitive outcomes in early age at onset MCI and dementia: Findings from the DIASPORA study
BACKGROUND: This study assessed the impact of cerebral small vessel disease (CSVD) on cognition in individuals with early‐onset (EO; β = 17.8, p = 0.013), remaining significant after adjusting for p‐tau217 and NfL, but not gray matter atrophy. Lacunes were associated with worse CDR plus NACC‐FTLD in EO ( β = 4.3, p = 0.011), with age‐dependent associations with MoCA, MMSE, CDR + NACC‐FTLD, and NPI‐Q ( p < 0.01). DISCUSSION: CSVD markers, although less prevalent in EO, had greater clinical impact. These findings highlight an increased vulnerability to vascular pathology in EO patients and the importance of early detection. Highlights: Cerebral small vessel disease (CSVD) markers were more impactful in early‐onset than late‐onset dementia. White matter hyperintensity (WMH) volume predicted functional decline in early onset, independent of neurodegeneration. Lacunes showed age‐dependent effects on multiple cognitive outcomes. Findings support early detection of CSVD in younger individuals with dementia.
- 14 October 2025
- Published by Wiley in Alzheimer's & Dementia
- Vol. 21 (10) , e70773
Open AccessImpact of cerebral small vessel disease on cognitive outcomes in early age at onset MCI and dementia: Findings from the DIASPORA study
BACKGROUND: This study assessed the impact of cerebral small vessel disease (CSVD) on cognition in individuals with early‐onset (EO; β = 17.8, p = 0.013), remaining significant after adjusting for p‐tau217 and NfL, but not gray matter atrophy. Lacunes were associated with worse CDR plus NACC‐FTLD in EO ( β = 4.3, p = 0.011), with age‐dependent associations with MoCA, MMSE, CDR + NACC‐FTLD, and NPI‐Q ( p < 0.01). DISCUSSION: CSVD markers, although less prevalent in EO, had greater clinical impact. These findings highlight an increased vulnerability to vascular pathology in EO patients and the importance of early detection. Highlights: Cerebral small vessel disease (CSVD) markers were more impactful in early‐onset than late‐onset dementia. White matter hyperintensity (WMH) volume predicted functional decline in early onset, independent of neurodegeneration. Lacunes showed age‐dependent effects on multiple cognitive outcomes. Findings support early detection of CSVD in younger individuals with dementia.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Safety and efficacy of acute ischemic stroke intervention in patients with cognitive decline: case‐control retrospective study
Background: Individuals diagnosed with mild cognitive impairment and dementia (MCI/Dem) are excluded from research on intervention for acute ischemic stroke; This research gap places stroke physicians worldwide in dilemmas while treating patients with cognitive decline. One example is acute stroke of large brain arteries, typically manifesting as immediate onset of severe neurological disability. Endovascular treatment (EVT), aka catheter‐base clot removal, is considered the gold‐standard treatment and when applied within hours after onset, can mitigate or reverse deficits and dramatically improve outcomes. Our goal was to evaluate efficacy and safety of EVT for acute stroke in MCI/Dem.Methods: This is a single site retrospective study from Rabin Medical Center,2019‐2021. Inclusion criteria was new onset acute large vessel stroke receiving EVT treatment, ages 18‐85 years. Pre‐stroke cognitive status was assessed using previous diagnosis, assessments in geriatric / occupational therapy clinics, nurse functional questionnaire and rehabilitation interview. Individuals were dichotomized to MCI/Dem (any severity) and unimpaired via consensus between two behavioural neurologists. The MCI/Dem group was matched to unimpaired individuals for sex, age, pre‐stroke functional independence, and stroke arterial territory, severity and time to EVT. The outcomes were retrospectively assessed 90 days after stroke and included mortality, intracranial haemorrhage, and pre to post stroke difference in the modified Rankin scale (mRS), commonly used instrument for stroke functional independence.Results: We identified 306 individuals with acute large vessel stroke who underwent EVT, of which 32 with pre‐stroke MCI/Dem. After matching, we saw no differences between non impaired group to MCI/Dem group in functional outcome measured by mRS change, (56% vs.53%, p = 0.8), brain hemorrhage(22% vs. 9%, p = 0.68) and mortality (25% vs. 12%,p = 0.2).Conclusion: To our knowledge this is the first study to report on EVT outcomes in individuals with MCI/Dem. Our results suggest interventions for acute large vessel stroke may have similar efficacy and safety profile in individuals with pre‐stroke MCI/Dementia and thus challenge previous recommendations to exclude them from therapy. Our data is retrospective and thus of inadequate design to suggest change to clinical guidelines. Further research on stroke interventions in MCI/Dem is urgently needed to guide day‐to‐day clinical decision making
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessSafety and efficacy of acute ischemic stroke intervention in patients with cognitive decline: case‐control retrospective study
Background: Individuals diagnosed with mild cognitive impairment and dementia (MCI/Dem) are excluded from research on intervention for acute ischemic stroke; This research gap places stroke physicians worldwide in dilemmas while treating patients with cognitive decline. One example is acute stroke of large brain arteries, typically manifesting as immediate onset of severe neurological disability. Endovascular treatment (EVT), aka catheter‐base clot removal, is considered the gold‐standard treatment and when applied within hours after onset, can mitigate or reverse deficits and dramatically improve outcomes. Our goal was to evaluate efficacy and safety of EVT for acute stroke in MCI/Dem.Methods: This is a single site retrospective study from Rabin Medical Center,2019‐2021. Inclusion criteria was new onset acute large vessel stroke receiving EVT treatment, ages 18‐85 years. Pre‐stroke cognitive status was assessed using previous diagnosis, assessments in geriatric / occupational therapy clinics, nurse functional questionnaire and rehabilitation interview. Individuals were dichotomized to MCI/Dem (any severity) and unimpaired via consensus between two behavioural neurologists. The MCI/Dem group was matched to unimpaired individuals for sex, age, pre‐stroke functional independence, and stroke arterial territory, severity and time to EVT. The outcomes were retrospectively assessed 90 days after stroke and included mortality, intracranial haemorrhage, and pre to post stroke difference in the modified Rankin scale (mRS), commonly used instrument for stroke functional independence.Results: We identified 306 individuals with acute large vessel stroke who underwent EVT, of which 32 with pre‐stroke MCI/Dem. After matching, we saw no differences between non impaired group to MCI/Dem group in functional outcome measured by mRS change, (56% vs.53%, p = 0.8), brain hemorrhage(22% vs. 9%, p = 0.68) and mortality (25% vs. 12%,p = 0.2).Conclusion: To our knowledge this is the first study to report on EVT outcomes in individuals with MCI/Dem. Our results suggest interventions for acute large vessel stroke may have similar efficacy and safety profile in individuals with pre‐stroke MCI/Dementia and thus challenge previous recommendations to exclude them from therapy. Our data is retrospective and thus of inadequate design to suggest change to clinical guidelines. Further research on stroke interventions in MCI/Dem is urgently needed to guide day‐to‐day clinical decision making
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Determinants of dementia phenotype in North African & Mid‐eastern Israelis
Background: Diverse ethnic ancestry and adverse social health determinants are increasingly recognized to impact dementia on multiple dimensions: genetically and environmentally determined risk, clinical presentation, detection, and the utility of cognitive testing and management. Most evidence originates from ethnically diverse cohorts in North America, with little representation of other world regions. We aimed to assess dementia clinical and neuroimaging phenotype in individuals of Middle Eastern and Northern African (MENA) descent, a population severely underrepresented in brain health research.Methods: The Alzheimer’s and atypical dementias in Israelis of diverse ancestry and disparate social health determinants (ADIDAS) project started on January 1st, 2022, and will prospectively recruit 200 individuals aged 40‐80 years reporting a new cognitive decline. The ADIDAS protocol includes APOE genotyping, structured assessment of early‐to‐late life social determinants, Israeli neighbourhood disadvantage index, medical history, vascular risk factors, cognitive testing, plasma Alzheimer’s biomarkers (Aβ40, Aβ42, total‐tau, p‐tau181, and NfL), and brain MRI. Ancestry was defined using participants and paternal country of birth. Countries were grouped into MENA, European, or neither, as defined by the World Bank. The project aims to assess the relationship between ethnic ancestry and associated social health determinants as predictors of brain neurodegeneration evident on neuroimaging and plasma biomarkers.Preliminary Results: As of January 1st, 2023, the ADIDAS cohort recruited 51 participants (55% female, mean age 65.8±8.4 years) of MENA (n = 24), European (n = 23), and neither (n = 3) ancestry. A preliminary comparison of MENA and European groups reveals MENA in our cohort are on average younger (63.87±8.9 vs. 68.3±8.2 years), have fewer years of schooling(11.7±2.5 vs. 16.2±3.4 years), and more likely to obtain only elementary or vocational education (75% vs. 13%). MENA were more likely to score poor results on cognitive testing‐ MMSE (21.6±4.9 vs. 24.8±5.5), receive a higher clinical dementia rating sum of boxes (3.4±2.5 vs. 1.45±1.4), and a lower carriage rate of apoE4 allele (11% vs. 30%).Conclusion: Preliminary non‐matched comparison suggests MENA with early‐stage cognitive impairment have a different social, cognitive, and genetic risk profile than individuals of European ancestry. Results of plasma biomarkers profile and MRI‐related structural changes will be shared at AAIC2023.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessDeterminants of dementia phenotype in North African & Mid‐eastern Israelis
Background: Diverse ethnic ancestry and adverse social health determinants are increasingly recognized to impact dementia on multiple dimensions: genetically and environmentally determined risk, clinical presentation, detection, and the utility of cognitive testing and management. Most evidence originates from ethnically diverse cohorts in North America, with little representation of other world regions. We aimed to assess dementia clinical and neuroimaging phenotype in individuals of Middle Eastern and Northern African (MENA) descent, a population severely underrepresented in brain health research.Methods: The Alzheimer’s and atypical dementias in Israelis of diverse ancestry and disparate social health determinants (ADIDAS) project started on January 1st, 2022, and will prospectively recruit 200 individuals aged 40‐80 years reporting a new cognitive decline. The ADIDAS protocol includes APOE genotyping, structured assessment of early‐to‐late life social determinants, Israeli neighbourhood disadvantage index, medical history, vascular risk factors, cognitive testing, plasma Alzheimer’s biomarkers (Aβ40, Aβ42, total‐tau, p‐tau181, and NfL), and brain MRI. Ancestry was defined using participants and paternal country of birth. Countries were grouped into MENA, European, or neither, as defined by the World Bank. The project aims to assess the relationship between ethnic ancestry and associated social health determinants as predictors of brain neurodegeneration evident on neuroimaging and plasma biomarkers.Preliminary Results: As of January 1st, 2023, the ADIDAS cohort recruited 51 participants (55% female, mean age 65.8±8.4 years) of MENA (n = 24), European (n = 23), and neither (n = 3) ancestry. A preliminary comparison of MENA and European groups reveals MENA in our cohort are on average younger (63.87±8.9 vs. 68.3±8.2 years), have fewer years of schooling(11.7±2.5 vs. 16.2±3.4 years), and more likely to obtain only elementary or vocational education (75% vs. 13%). MENA were more likely to score poor results on cognitive testing‐ MMSE (21.6±4.9 vs. 24.8±5.5), receive a higher clinical dementia rating sum of boxes (3.4±2.5 vs. 1.45±1.4), and a lower carriage rate of apoE4 allele (11% vs. 30%).Conclusion: Preliminary non‐matched comparison suggests MENA with early‐stage cognitive impairment have a different social, cognitive, and genetic risk profile than individuals of European ancestry. Results of plasma biomarkers profile and MRI‐related structural changes will be shared at AAIC2023.
- 1 March 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 410, 116663
Meningitis without meningeal irritation signs: What are the alerting clinical markers?
- 1 March 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 410, 116663
Meningitis without meningeal irritation signs: What are the alerting clinical markers?
- 11 September 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 65 (3) , 877-884
Non-Ashkenazi Jewish Origin is Associated with Early Onset Alzheimer’s Disease
Early-onset Alzheimer’s disease (EOAD) accounts for 1–5% of Alzheimer’s disease cases and is associated with specific ethnicities. It has been our impression that non-Ashkenazi Jews have a higher rate of EOAD and we therefore explored this hypothesis
- 11 September 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 65 (3) , 877-884
Non-Ashkenazi Jewish Origin is Associated with Early Onset Alzheimer’s Disease
Early-onset Alzheimer’s disease (EOAD) accounts for 1–5% of Alzheimer’s disease cases and is associated with specific ethnicities. It has been our impression that non-Ashkenazi Jews have a higher rate of EOAD and we therefore explored this hypothesis
- Open Access
- 1 January 2016
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 12 (4) , 403-406
Seasonal Changes in the Incidence of Transient Global Amnesia
Transient global amnesia (TGA) is a stereotypic condition characterized by anterograde and retrograde amnesia that typically resolves within 24 hours. The pathophysiology of TGA is still unclear. We noted that patients hospitalized with TGA tend to appear in seasonal clusters, and decided to investigate this phenomenon. Every patient with acute presentation of amnesia at our medical center is hospitalized for observation and evaluation. We reviewed the monthly occurrence of TGA in our patient population between 2000 and 2014, and compared this to non-TGA hospitalizations during the same time period. During the analysis period, 154 patients who met the criteria for TGA were hospitalized, as well as 259,007 non-TGA hospitalizations. The annual occurrence of TGA ranged from 5 to 16 hospitalizations. There were 91 TGA events in women and 63 in men, in subjects aged 62.8±10.6 years (mean±SD). The incidence was maximal during December [odds ratio (OR)=2.83, 95% confidence interval (CI)=1.20–6.67] and March (OR=2.77, 95% CI=1.17–6.56), and minimal from April to August. The incidence exhibited an increase followed by a decrease from October to February. A seasonal trend was observed as well, with incidence peaks occurring in winter (OR=1.82, 95% CI=1.12–2.96) and spring (OR=1.80, 95% CI=1.10–2.94). Our findings suggest that the incidence of TGA exhibits seasonal variations. This observation may help to improve the understanding of the pathophysiology underlying TGA.
- 1 January 2016
- Published by Korean Neurological Association in Journal of Clinical Neurology
- Vol. 12 (4) , 403-406
Open AccessSeasonal Changes in the Incidence of Transient Global Amnesia
Transient global amnesia (TGA) is a stereotypic condition characterized by anterograde and retrograde amnesia that typically resolves within 24 hours. The pathophysiology of TGA is still unclear. We noted that patients hospitalized with TGA tend to appear in seasonal clusters, and decided to investigate this phenomenon. Every patient with acute presentation of amnesia at our medical center is hospitalized for observation and evaluation. We reviewed the monthly occurrence of TGA in our patient population between 2000 and 2014, and compared this to non-TGA hospitalizations during the same time period. During the analysis period, 154 patients who met the criteria for TGA were hospitalized, as well as 259,007 non-TGA hospitalizations. The annual occurrence of TGA ranged from 5 to 16 hospitalizations. There were 91 TGA events in women and 63 in men, in subjects aged 62.8±10.6 years (mean±SD). The incidence was maximal during December [odds ratio (OR)=2.83, 95% confidence interval (CI)=1.20–6.67] and March (OR=2.77, 95% CI=1.17–6.56), and minimal from April to August. The incidence exhibited an increase followed by a decrease from October to February. A seasonal trend was observed as well, with incidence peaks occurring in winter (OR=1.82, 95% CI=1.12–2.96) and spring (OR=1.80, 95% CI=1.10–2.94). Our findings suggest that the incidence of TGA exhibits seasonal variations. This observation may help to improve the understanding of the pathophysiology underlying TGA.
- 1 June 2013
- Vol. 15 (6) , 308-12
Biomedical synthetic biology: an overview for physicians.
Synthetic bioiogy is a ,relatively new fieild of bologlcal research and development that focases on the engineering of genetic molecular machlnes wIth a specific predefined function. Plainly put the newly engineered organism functions as a machine. It can process information. manufature, heal and even diagnose. We just have to engineer It to do so. The famous quote "Biology Is the nanotechnology that works" is currently being put to the test on a worldwide scale. The application of these machines Is theoretically boundless. In laboratories worldwide synthetic biology technologies are being rationally designed to assist in diagnosis or disrupt disease mechnisms. In the not too distant future they are expected to reach the clinical setting. This new field should be distinguished from classic genetic engineering. The latter researches naturalfy found DNA segments via cloning. It is weakly associated with engineering. Synthetic biology focuses on the engineering of molecular biological machines for the benefit of mankind. This is done via synthetic (computer printed) DNA sequences, man-designed or altered in silico. In this article I will briefly introduce synthetic biology, elaborate on the BiobrickFoundation as an independent fast-growing synthetic biology-sharing movement, and report on selected developing applications for medicine.
- 1 June 2013
- Vol. 15 (6) , 308-12
Biomedical synthetic biology: an overview for physicians.
Synthetic bioiogy is a ,relatively new fieild of bologlcal research and development that focases on the engineering of genetic molecular machlnes wIth a specific predefined function. Plainly put the newly engineered organism functions as a machine. It can process information. manufature, heal and even diagnose. We just have to engineer It to do so. The famous quote "Biology Is the nanotechnology that works" is currently being put to the test on a worldwide scale. The application of these machines Is theoretically boundless. In laboratories worldwide synthetic biology technologies are being rationally designed to assist in diagnosis or disrupt disease mechnisms. In the not too distant future they are expected to reach the clinical setting. This new field should be distinguished from classic genetic engineering. The latter researches naturalfy found DNA segments via cloning. It is weakly associated with engineering. Synthetic biology focuses on the engineering of molecular biological machines for the benefit of mankind. This is done via synthetic (computer printed) DNA sequences, man-designed or altered in silico. In this article I will briefly introduce synthetic biology, elaborate on the BiobrickFoundation as an independent fast-growing synthetic biology-sharing movement, and report on selected developing applications for medicine.